News & Events
KaloBios Initiates Phase 1 Clinical Trial of KB004 in EphA3-Expressing Hematologic Malignancies
25 / 03 / 2011
ChemGenex to Align European and US Regulatory Strategies for Omacetaxine
05 / 01 / 2011
â?¢ Existing Marketing Authorization Application (MAA) for omacetaxine in T315I positive CML patients to be withdrawn â?¢ ChemGenex to submit a new MAA for omacetaxine in larger population of CML patients who have failed two or more tyrosine kinase inhibitors
Displaying records 51-60 of 60